119th Congress · introduced in the House · Feb 21, 2025
To prohibit the use of Federal funds to implement, administer, or enforce a final rule of the Food and Drug Administration relating to "Medical Devices; Laboratory Developed Tests", and for other purposes.
Official title from Congress.gov
Latest action (Feb 21, 2025): Referred to the House Committee on Energy and Commerce.
View on Congress.govPolicy area: Health
Congressional Research Service summary, version: Introduced in House (Feb 21, 2025)
This bill prohibits the use of federal funds to implement, administer, or enforce the final rule issued by the Food and Drug Administration (FDA) titled Medical Devices; Laboratory Developed Tests and published on May 6, 2024, or any substantially similar rule.
The rule specifies that laboratory developed tests (medical screening tests developed by laboratories rather than medical device manufacturers) are medical devices subject to FDA regulation with limited exceptions. Prior to the rule, the FDA had exercised discretion as to whether to apply regulations for medical devices to laboratory developed tests.
Includes amendment, cloture, and procedural votes. Each is labeled with its exact question; only a passage question is a vote to pass the bill.
No recorded roll calls on this bill in coverage.
Referred to the House Committee on Energy and Commerce.
Introduced in House
Introduced in House
Actions from Congress.gov, newest first.
Administrative law and regulatory procedures · Drug safety, medical device, and laboratory regulation · Food and Drug Administration (FDA) · Health programs administration and funding · Medical tests and diagnostic methods
LD-2 reports whose issue descriptions explicitly cite this bill (bill type and number validated against Congress.gov records). A citation does not establish the client's position or any contact with a member.
Loading lobbying reportsCoverage: reports for 2025 onward, posted Jan 1, 2025 through Oct 24, 2026.
5 citations.
COLLEGE OF AMERICAN PATHOLOGISTS · lobbying firm or registrant: COLLEGE OF AMERICAN PATHOLOGISTS
2025 Q4 report (Oct 1, 2025 – Dec 31, 2025) · posted Jan 20, 2026 · issue area: Health Issues
$154,425
Spent on own lobbying
…Physician Access Reauthorization Act S. 1380 - SPARC Act S. 942/H.R. 2028 - REDI Act H.R. 879 - Medicare Patient Access and Practice Stabilization Act of 2025 H.R. 1463 - To prohibit the use of Federal funds to implement, administer, or enforce a final rule of the Food and Drug Administration relating to "Medical Devices; Labo…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
COLLEGE OF AMERICAN PATHOLOGISTS · lobbying firm or registrant: COLLEGE OF AMERICAN PATHOLOGISTS
2025 Q3 report (Jul 1, 2025 – Sep 30, 2025) · posted Oct 17, 2025 · issue area: Health Issues
$124,816
Spent on own lobbying
…Physician Access Reauthorization Act S. 1380 - SPARC Act S. 942/H.R. 2028 - REDI Act H.R. 879 - Medicare Patient Access and Practice Stabilization Act of 2025 H.R. 1463 - To prohibit the use of Federal funds to implement, administer, or enforce a final rule of the Food and Drug Administration relating to "Medical Devices; Labo…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
COLLEGE OF AMERICAN PATHOLOGISTS · lobbying firm or registrant: COLLEGE OF AMERICAN PATHOLOGISTS
2025 Q2 report (Apr 1, 2025 – Jun 30, 2025) · posted Jul 18, 2025 · issue area: Health Issues
$149,447
Spent on own lobbying
…Physician Access Reauthorization Act S. 1380 - SPARC Act S. 942/H.R. 2028 - REDI Act H.R. 879 - Medicare Patient Access and Practice Stabilization Act of 2025 H.R. 1463 - To prohibit the use of Federal funds to implement, administer, or enforce a final rule of the Food and Drug Administration relating to "Medical Devices; Labo…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
COLLEGE OF AMERICAN PATHOLOGISTS · lobbying firm or registrant: COLLEGE OF AMERICAN PATHOLOGISTS
2025 Q1 report (Jan 1, 2025 – Mar 31, 2025) · posted Apr 16, 2025 · issue area: Health Issues
$217,588
Spent on own lobbying
…Physician Access Reauthorization Act S. 1380 - SPARC Act S. 942/H.R. 2028 - REDI Act H.R. 879 - Medicare Patient Access and Practice Stabilization Act of 2025 H.R. 1463 - To prohibit the use of Federal funds to implement, administer, or enforce a final rule of the Food and Drug Administration relating to "Medical Devices; Labo…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
CHIPPS, CAFFREY AND DUBILIER, P. S. C. · lobbying firm or registrant: GABBERT CONSULTING CO LLC
2025 Q1 report (Jan 1, 2025 – Mar 31, 2025) · posted Apr 1, 2025 · issue area: Medical/Disease Research/Clinical Labs
$9,000
Paid to lobbying firm
Supported HR 1463 a bill that restricts funding for FDA's LDT ruling
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing